

| |
|------|
| |
| |
| |
| |
| |
| |
| |

Current Projects


Reducing Cost of Abstracting; Refreshing Real-Time Reports


- Completeness Report migration (released: 2023)
- Call for Data 2.0 (2024)
- Benchmark and Site by Stage migration (2024)




ACS NCDB Mendian

ACS NCDB National Canage Database









Benefits of Call 4 Data 2.0

- Cohorts will be complete one year sooner
- Warehouse and NCDB Tools can be built one year sooner, and earlier in the year • Decrease in bandwidth of RCRS case submissions, lower costs
- Less busy work for CTRs
- Less concentrated, emergent NCDB customer service support
- Cohorts will be submitted before annual release of new NAACCR version
 RCRS supports 2 NAACCR versions
 - Some hospitals have vendor challenges when new version released

13

Example 2024

Last Call 4 Data

Call for Data March 1-31, 2024
 17mm cases submitted

- Dx 2008-2022
- Warehouse and Tools created with 2022 data
 May September
- Most current year of complete cases is 2022 for 2025 Site Reviews
- Call 4 Data 2.0
- Call for Data Dec 31, 2024
 Registrars work edit errors and submit any new cases in December (3.5mm cases)

ACS NCDB Minut Court Database

ACS NCDB National Concer Detabase

- DX 2009-2023
 Warehouse and T
- Warehouse and Tools created with 2023 data Feb-May

ACS NCDB


• Most current year of complete cases is 2023 for 2025 Site Reviews

14


Next Steps


• No changes to 6.4, 6.5 for 2024

- Call 4 Data changes can be made w/o changing Accreditation standard
 2023 Release Completeness Report in RCRS
 - Data Item Completeness
- Cohort Completeness (relative to prior years)
- 2024 Last Call for Data, March
- Collection of 2022 cases
- December 31, 2024, Call for Data 2.0 • Complete cases for DX 2023
 - No resubmission of cases that are already current from monthly RCRS sub
 - 92% of complete cases already exist in RCRS before current C4D



| | | | | | | | ACS NODE | Reflevel Center Defailane American College of Surgeon |
|------|---------------------|--------|----------------------------|--------|--------|--------|---------------|--|
| | | | C ompl egistrars | | - | | sion standard | d (90% rule) |
| Ste | Cohort Case Cou | nt | | | | | | |
| | Site | Dx2023 | Dx2022 | Dx2021 | Dx2020 | Dx2019 | | |
| | DINECK | 83 | 87 | 68 | 97 | 123 | | |
| KODA | | 122 | 151 | 146 | 105 | 113 | | |
| LUN | | 300 | 344 | 322 | 281 | 296 | | |
| | ANOMA | 243 | 305 | 329 | 166 | 247 | | |
| | CREAS | 98 | 124 | 120 | 100 | 135 | | |
| | STATE | 367 | 409 | 494 | 443 | 528 | | |
| | TUM | 49 | 55 | 64 | 38 | 64 | | |
| | ROID OTHER SITES | 97 | 140 | 145 | 108 | 136 | | |
| | AL COHORT | 313 | 4161 | 4272 | 3592 | 4255 | | |
| 101 | AL COHORT | 3428 | 4101 | 42/2 | 35962 | 4255 | | 6 |
| Ste | Cohort Totals | | | | | | | |
| | 4500 | | | 2000 | | 672 | | 611 |
| | 4000 | | _ | 4101 | | | | |
| | 3500 | 2425 | | | | | 2542 | |
| | 3000 | | | | | | | |
| | 2500 | | | | | | | |
| | | | | | | | | |
| | 2000 | | | | | | | |
| | 1500 | | | | | | | |
| | 1000 | | | | | | | |
| | 500 | | | | | | | |
| | | Dw2123 | | 0+2122 | | -2021 | 0x2020 | 042019 |
| | | | | | | | | |





2024 Quality Measures in RCRS – this spring

 For patients with any stage cervical cancer treated with primary radiation with curative intent, brachytherapy is used.

For patients with low grade Ta bladder cancer undergoing transurethral resection of bladder tumor, intravesical chemotherapy is administered within 24 hours of the procedure.

ACS NCDB

- For patients with low-risk prostate cancer (Gleason <= 6 and PSA < 10 and <= cT2), active surveillance is performed.
- For patients with surgically managed, cT1a kidney tumors, partial nephrectomy is performed.

| For patients <= 75 years old with HER2+ or | | | March Street of | 27 | 100 | And in case of | And and | ACCOUNTS ON THE OWNER | - | - | |
|---|-------|-----|---|-----|-------|----------------|------------------------|--|---------|----------|---------|
| triple negative breast cancer with any clinical N | | *** | and an other and the first | 27. | | - | 10. cm | | (it and | 20. are | 20 |
| > 0 or clinical T > 1, neoadjuvant chemotherapy | 1 | - | Res 2 Martine angli - meter a manufacture dan dan dan dan 1 Martine 1 Martine - Martine and Antonio State and Stat | 22 | - | - | | in | | - | <u></u> |
| and/or immunotherapy is initiated within 60 | 1.00 | ** | signi d'access capite agent lond const le comme son le qui è sui provi de server activa parte l'acte prise de la dessit compet activa parte l'acte parte de la dessit competence a longe de la competence de la competence de la competence de la competence de la competence de la competence de la co | 27 | - | - | | | | | |
| days of diagnosis, or recommended. | | | The address managed as a risk manifest the same second of the of the space of the state on the same second single do manifest of the of the state. | 27. | 10.75 | - | - | (22 | | 22. www. | |
| iyo or alagnosis, or recommended. | - | - | the second constraints of the second se | 27 | 222 | | - | 1000 - 100 - | - | | |
| For patients with surgically treated clinical | | | in contract of the set | 27 | 22.22 | | | | | | |
| T4NanyM0 or TanyN2M0 rectal cancer, | name. | - | Interface and any set of the address of the set of t | No. | - | - | 140 100 × 100 10 | 100.000 | 100.000 | | |
| neoadjuvant radiation therapy is initiated | | - | the second | 217 | 20.00 | - | - | | | | |
| within 9 months prior to resection or | ***** | * | For anyon the compact offering in the Work intervent advect above control for an intervention of the control of the property of the control of the control of the control of Property of the control of t | 22 | 10.22 | - | - | | | fil an | - |

